Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome - Positive acute lymphoblastic leukemia

Leukemia

Volumn 27, Issue 6, 2013, Pages 1411-1413

  Ottmann, O G ^a   Larson, R A ^b   Kantarjian, H M ^c   Le Coutre, P D ^d   Baccarani, M ^e   Hochhaus, A ^f   Kim, D W ^g   Fan, X ^h   Novick, S ^h   Giles, F J ⁱ  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g The Catholic University of Korea   (South Korea)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; IMATINIB; METHOTREXATE; NILOTINIB;

ABNORMAL LABORATORY RESULT; ACUTE LYMPHOBLASTIC LEUKEMIA; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BASOPHIL; BLOOD SAMPLING; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CYTOGENETICS; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFORMED CONSENT; LETTER; LIVER FUNCTION; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PILOT STUDY; PLASMA CLEARANCE; PRIORITY JOURNAL; RECURRENCE RISK; SAMPLE SIZE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WILD TYPE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECURRENCE; YOUNG ADULT;

EID: 84878907482     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.324     Document Type: Letter

References (14)

1. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 117: 1583-1594.
2. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110: 2309-2315. (Pubitemid 47523149)
3. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141. (Pubitemid 40248339)
4. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941-4947. (Pubitemid 41557215)
5. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551. (Pubitemid 43882350)
6. Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Gehrke B, Petershofen EK et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (PhALL) during imatinib treatment. Leukemia 2003; 17: 1700-1706. (Pubitemid 37185243)
7. Merante S, Colombo AA, Calatroni S, Rocca B, Boni M, Bernasconi P et al. Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplant 2009; 44: 263-264.
8. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33: 174-177.
9. Castillo E, Al-Rajabi R, Pandya DM, Varadarajan P, Kelly KR, Swords R et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia. Blood 2010; 116: 885-886(abstract 2144).
10. US National Institutes of Health. Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (NCT00844298), Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/ show/NCT00844298?term=nilotinibacutelymphoblasticleukemia&rank=2. Published 13 February 2009. Updated 2012 (accessed) 7 June 2012.
11. U.S. National Institutes of Health. Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi) (NCT00905398), Clinicaltrials.gov Web site. http://www.clinicaltrials. gov/ct2/show/NCT00905398?term=nilotinibacutelymphoblasticleukemia&rank=4. Published 2009. Updated 2009 (accessed) 7 June 2012.
12. US National Institutes of Health. Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT01528085), Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01528085? term=nilotinib acutelymphoblasticleukemia&rank=1. Published 3 February 2012. Updated 2012 (accessed) 7 June 2012.
13. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011; 25: 1314-1323.
14. Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi SJ et al. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology 2012; 1: 618-629.